2-Methoxyqualone: New 2026 Quaalude Analogue Signal With Almost No Human Data

2-Methoxyqualone: New 2026 Quaalude Analogue Signal With Almost No Human Data

Quick answer

2-Methoxyqualone is a newly emerging quinazolinone research chemical structurally related to methaqualone.

CFSRE reported confirmed U.S. drug-material detections and published a monograph in April 2026.

At that point, the evidence was exceptionally thin: CFSRE reported no published pharmacological potency data and no toxicology cases in its dataset.

That makes 2-methoxyqualone a textbook example of a drug reaching the market before the human evidence exists.

What was actually detected

CFSRE reported 2-methoxyqualone in two drug materials originating from Pennsylvania and California.

The compound was identified as the sole reported component in those specimens.

Forensic confirmation establishes chemical presence. It does not establish safe human use.

What is expected pharmacologically

Because of structural similarity to methaqualone, sedative-hypnotic effects are hypothesized.

That is an inference.

Without controlled pharmacology, we do not have a reliable human potency comparison, therapeutic index, half-life, interaction profile or overdose threshold.

Why community reports cannot fill the gap

Online reports may eventually describe subjective effects, but they generally cannot verify:

• compound identity;
• purity;
• active concentration;
• co-ingredients;
• metabolism;
• population-level adverse-event rates.

For a new RC, anecdotal confidence can grow much faster than scientific knowledge.

Depressant risk remains relevant

If 2-methoxyqualone does produce substantial GABAergic sedation, combining it with alcohol, benzodiazepines, opioids or other depressants could plausibly increase impairment and overdose risk.

The absence of documented interaction studies is not evidence of safety.

Related evidence

• Novel sedatives & qualone analogues
• Dicloqualone / SL-164
• Designer benzodiazepines
• Research chemicals & NPS evidence map

Evidence boundaries that matter in practice

The central safety problem with 2-methoxyqualone is not that a particular toxic effect has already been quantified; it is that basic human pharmacology is still missing while real drug-material detections already exist. That mismatch changes how the evidence should be read. Structural similarity can justify hypotheses about a sedative profile, but it cannot establish a human half-life, a therapeutic window, a reliable potency comparison, or a predictable interaction magnitude.

A second limitation is the difference between drug-material evidence and clinical evidence. An analytically confirmed powder proves that the compound reached the supply. It does not tell us how often people are exposed, whether material sold under the same name is chemically consistent, or which symptoms would occur at a given exposure. Until toxicology casework accumulates, claims about a characteristic human syndrome should remain provisional.

Dependence and withdrawal

There is not enough direct human evidence to publish a 2-methoxyqualone-specific withdrawal timeline. If the compound produces sustained sedative-hypnotic activity, repeated exposure could plausibly create tolerance or physical dependence, but that remains a class- and mechanism-informed concern rather than a measured incidence estimate for this molecule. The site therefore should not turn anecdotal withdrawal reports into a fixed day-by-day schedule.

Testing and product identity

Routine point-of-care drug screens are not designed to identify every novel quinazolinone. Confirming an unusual compound generally requires a laboratory method capable of separating and identifying the analyte with an appropriate reference standard or high-resolution spectral evidence. A negative routine screen therefore cannot establish that an unknown sedative product is free of 2-methoxyqualone or related analogues.

The safest evidence summary is deliberately conservative: the compound is analytically real, human effects are poorly characterized, and uncertainty itself is part of the risk. That is more useful than filling the gaps with borrowed claims from methaqualone or online experience reports.

Bottom line

2-Methoxyqualone is notable precisely because the market signal is ahead of the science.

The most accurate 2026 description is not “new Quaalude.” It is newly detected methaqualone analogue with almost no human evidence.